If DLBCL patients were separated into groups of low and high mRNA expression with average CYLD expression as cutoff, the median overall survival was below 6 years in the CYLD low patients, while it was over 10 years in the CYLD high patients (Fig. 1B). This evidence concerns the gene CYLD and diffuse large B-cell lymphoma.